Investigating early ageing in young cancer patients during treatment
Longitudinal Assessment of Therapy-related Early Ageing in Adolescent and Young Adult (AYA) Cancer Patients
University Medical Center Groningen · NCT05062707
This study is trying to see how cancer treatment affects early aging and heart health in young adults aged 18-39 who are undergoing therapy for cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 39 Years |
| Sex | All |
| Sponsor | University Medical Center Groningen (other) |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Groningen) |
| Trial ID | NCT05062707 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess early ageing and cellular senescence in adolescent and young adult (AYA) cancer patients aged 18-39 years. It involves a longitudinal cohort design where participants will undergo blood sampling before starting systemic therapy and again one year later. The study seeks to identify markers related to early vascular ageing and understand the impact of cancer treatment on long-term health outcomes, particularly cardiovascular disease. By focusing on this under-researched population, the study hopes to fill gaps in knowledge regarding the long-term effects of cancer therapies on AYA patients.
Who should consider this trial
Good fit: Ideal candidates are AYA patients aged 18-39 with a confirmed cancer diagnosis who are scheduled to start systemic therapy.
Not a fit: Patients who have previously received systemic therapy or radiotherapy for another malignancy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management strategies for cardiovascular health in young cancer survivors.
How similar studies have performed: While there is limited research specifically on AYA cancer patients, studies on early ageing in other cancer survivor populations suggest potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18-39 years at cancer diagnosis * Having a histologically and/or cytologically confirmed cancer diagnosis, including leukemia, (non-)Hodgkin lymphoma, testicular cancer, osteosarcoma, Ewing sarcoma, breast cancer, and cervical cancer. * Scheduled to start systemic therapy with curative intent. Allowed treatments (concurrent or sequential) are: surgery, radiotherapy, chemotherapy, antibodies. Exclusion Criteria: * patients who are not able to understand the patient information letter and informed consent form * patients who will be treated with immune checkpoint inhibitors or targeted therapy with inhibitors of angiogenesis * patients who have been treated with systemic therapy or radiotherapy for a previous malignancy (exceptions: in situ carcinoma of the cervix or uterus and adequately treated basal and squamous cell carcinoma of the skin).
Where this trial is running
Groningen
- University Medical Center Groningen — Groningen, Netherlands (RECRUITING)
Study contacts
- Principal investigator: J. Nuver, MD, PhD — University Medical Center Groningen
- Study coordinator: J. Nuver, MD, PhD
- Email: j.nuver@umcg.nl
- Phone: +31 50 361 2821
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer, Leukemia, Hodgkin Lymphoma, Testicular Cancer, Osteosarcoma, Ewing Sarcoma, Breast Cancer, Cervical Cancer